
  
    
      
        Introduction_NNP
        A_DT number_NN of_IN studies_NNS have_VBP evaluated_VBN possible_JJ associations_NNS
        between_IN a_DT polymorphism_NN in_IN the_DT cytochrome_NN P_NN 450_CD c_SYM 17_CD α_NN (_( 
        CYP_NNP 17_CD )_) gene_NN and_CC breast_NN cancer_NN risk_NN [_NN
        1_CD 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD 9_CD 10_CD 11_CD 12_CD 13_CD 14_CD 15_CD 16_CD ]_NN ._. Cytochrome_NNP
        P_NN 450_CD c_SYM 17_CD α_NN functions_NNS at_IN key_JJ branch_NN points_NNS in_IN human_JJ
        steroidogenesis_NNS ,_, catalyzing_VBG the_DT ovarian_NN and_CC adrenal_NN
        biosynthesis_NNS pathways_NNS for_IN androstenedione_NN ,_, the_DT immediate_JJ
        precursor_NN of_IN testosterone_NN [_NN 17_CD ]_NN ._. Three_CD polymorphisms_NNS have_VBP
        been_VBN described_VBN in_IN this_DT gene_NN :_: a_DT C_NNP →_NN T_NN transition_NN at_IN
        nucleotide_NN 5471_CD in_IN intron_NN 6_CD [_NN 18_CD ]_NN ,_, a_DT G_NNP →_NN A_DT transition_NN at_IN
        nucleotide_NN 47_CD in_IN the_DT 5_CD '_POS -_: untranslated_JJ region_NN promoter_NN [_NN 19_CD ]_NN
        ,_, and_CC a_DT thymidine_NN substitution_NN for_IN cytosine_NN at_IN nucleotide_NN
        27_CD in_IN the_DT 5_CD '_POS -_: untranslated_JJ region_NN promoter_NN that_WDT creates_VBZ a_DT 
        Msp_NNP AI_NNP recognition_NN site_NN [_NN 20_CD ]_NN ._.
        The_DT 
        Msp_NNP AI_NNP polymorphism_NN gives_VBZ rise_NN to_TO
        three_CD genotypes_NNS (_( A_DT 1_CD /_NN A_DT 1_CD ,_, A_DT 1_CD /_NN A_DT 2_CD ,_, and_CC A_DT 2_CD /_NN A_DT 2_LS )_) ._. Although_IN it_PRP was_VBD
        hypothesized_VBN that_IN the_DT polymorphism_NN (_( A_DT 2_CD allele_NN )_) could_MD result_VB
        in_IN an_DT additional_JJ Sp_NNP 1_CD binding_JJ site_NN with_IN enhanced_JJ promoter_NN
        activity_NN and_CC an_DT increased_VBN rate_NN of_IN transcription_NN [_NN 1_CD ]_NN ,_,
        this_DT was_VBD not_RB found_VBN in_IN experimental_JJ studies_NNS [_NN 20_CD 21_CD ]_NN ._.
        Nonetheless_RB ,_, two_CD studies_NNS found_VBD that_IN both_DT premenopausal_NN and_CC
        post-menopausal_JJ women_NNS with_IN the_DT variant_NN A_DT 2_CD allele_NN had_VBD higher_JJR
        levels_NNS of_IN circulating_VBG estrogens_NNS than_IN those_DT with_IN common_JJ
        alleles_NNS ,_, indicating_VBG that_IN the_DT polymorphism_NN may_MD be_VB in_IN linkage_NN
        disequilibrium_NN with_IN another_DT functional_JJ polymorphism_NN or_CC that_IN
        it_PRP may_MD affect_VB hormone_NN levels_NNS through_IN some_DT other_JJ mechanism_NN [_NN
        4_CD 22_CD ]_NN ._.
        Effects_NNPS of_IN the_DT variant_NN 
        CYP_NNP 17_CD genotype_NN on_IN risk_NN have_VBP been_VBN
        investigated_VBN in_IN a_DT number_NN of_IN studies_NNS ,_, with_IN some_DT
        corroborative_JJ results_NNS and_CC some_DT conflicting_JJ results_NNS ._. In_IN a_DT
        multiethnic_JJ cohort_NN ,_, while_IN breast_NN cancer_NN risk_NN was_VBD not_RB
        significantly_RB increased_VBN for_IN women_NNS with_IN the_DT A_DT 2_CD allele_NN [_NN 1_CD ]_NN
        ,_, the_DT A_DT 2_CD allele_NN did_VBD confer_VB more_JJR than_IN a_DT twofold_NN increase_NN in_IN
        risk_NN among_IN those_DT with_IN advanced_JJ disease_NN ._. Furthermore_RB ,_, late_JJ
        age_NN at_IN menarche_NN was_VBD protective_JJ only_RB among_IN women_NNS who_WP were_VBD
        homozygous_JJ for_IN the_DT A_DT 1_CD allele_NN ._. The_DT findings_NNS regarding_VBG age_NN at_IN
        menarche_NN were_VBD confirmed_VBN in_IN three_CD other_JJ studies_NNS [_NN 2_CD 4_CD 9_CD ]_NN
        and_CC in_IN a_DT recent_JJ meta-analysis_JJ involving_VBG 4227_CD cases_NNS and_CC 4730_CD
        controls_NNS [_NN 16_CD ]_NN ._. These_DT studies_NNS did_VBD not_RB find_VB that_IN the_DT 
        CYP_NNP 17_CD genotype_NN was_VBD associated_VBN with_IN
        risk_NN of_IN breast_NN cancer_NN ,_, even_RB when_WRB stratifying_VBG by_IN stage_NN of_IN
        disease_NN [_NN 4_CD 9_CD 16_CD ]_NN ._.
        Feigelson_NNP 
        et_CC al_NN ._. [_NN 23_CD ]_NN recently_RB reported_VBD that_IN
        women_NNS with_IN A_DT 2_CD alleles_NNS were_VBD less_RBR likely_JJ than_IN those_DT with_IN A_DT 1_CD
        alleles_NNS to_TO use_VB hormone_NN replacement_NN therapy_NN ,_, presumably_RB
        because_IN of_IN fewer_JJR menopausal_NN symptoms_NNS due_JJ to_TO higher_JJR
        circulating_VBG estrogens_NNS ._. It_PRP is_VBZ clear_JJ that_DT hormonal_NN milieu_NN
        differs_VBZ for_IN pre-menopausal_JJ women_NNS and_CC postmenopausal_NN women_NNS ,_,
        and_CC there_EX is_VBZ evidence_NN that_IN risk_NN factors_NNS for_IN disease_NN
        diagnosed_VBN among_IN the_DT two_CD groups_NNS of_IN women_NNS may_MD also_RB differ_VB ,_,
        particularly_RB those_DT related_VBN to_TO hormonal_NN factors_NNS [_NN 24_CD ]_NN ._.
        The_DT majority_NN of_IN previous_JJ studies_NNS did_VBD not_RB evaluate_VB
        associations_NNS separately_RB by_IN menopausal_NN status_NN ,_, particularly_RB
        for_IN effect_NN modification_NN by_IN 
        CYP_NNP 17_CD on_IN relationships_NNS between_IN breast_NN
        cancer_NN and_CC other_JJ risk_NN factors_NNS ._. In_IN the_DT present_JJ study_NN ,_, we_PRP
        evaluated_VBD ,_, separately_RB for_IN premenopausal_NN and_CC postmenopausal_NN
        women_NNS ,_, whether_IN the_DT 
        CYP_NNP 17_CD polymorphism_NN was_VBD independently_RB
        related_VBN to_TO breast_NN cancer_NN risk_NN or_CC could_MD possibly_RB act_VB through_IN
        modification_NN of_IN other_JJ breast_NN cancer_NN risk_NN factors_NNS ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Population_NNP
          These_DT research_NN data_NN were_VBD collected_VBN in_IN an_DT earlier_JJR
          case-control_JJ study_NN (_( 1986_CD -_: 1991_CD )_) of_IN 617_CD premenopausal_NN and_CC
          933_CD postmenopausal_NN Caucasian_NNP women_NNS in_IN western_JJ New_NNP York_NNP ._.
          The_DT detailed_VBN methods_NNS have_VBP been_VBN reported_VBN elsewhere_RB [_NN 25_CD 26_CD
          27_CD ]_NN ._.
          The_DT protocol_NN for_IN the_DT present_JJ study_NN was_VBD reviewed_VBN by_IN the_DT
          Institutional_NNP Review_NNP Board_NNP of_IN the_DT State_NNP University_NNP of_IN New_NNP
          York_NNP at_IN Buffalo_NNP and_CC by_IN all_DT of_IN the_DT participating_VBG
          hospitals_NNS ._. Informed_NNP consent_NN was_VBD received_VBN from_IN all_DT
          participants_NNS for_IN the_DT interview_NN and_CC for_IN the_DT medical_JJ record_NN
          review_NN ._. Women_NNP diagnosed_VBD with_IN incident_NN ,_, primary_JJ ,_,
          histologically_RB confirmed_VBD breast_NN cancer_NN were_VBD identified_VBN at_IN
          all_DT major_JJ hospitals_NNS in_IN Erie_NNP and_CC Niagara_NNP counties_NNS ._. They_PRP
          were_VBD frequency_NN matched_VBN by_IN age_NN and_CC county_NN of_IN residence_NN
          with_IN controls_NNS randomly_RB selected_VBN from_IN the_DT New_NNP York_NNP State_NNP
          Motor_NNP Vehicle_NNP lists_NNS (_( <_NN 65_CD years_NNS )_) and_CC the_DT Health_NNP Care_NNP
          Finance_NNP Administration_NNP rolls_NNS (_( >_NN 65_CD years_NNS )_) ._. Interview_NNP
          data_NNS included_VBD medical_JJ ,_, reproductive_JJ ,_, dietary_JJ ,_, and_CC
          lifestyle_NN histories_NNS ._. The_DT majority_NN of_IN women_NNS were_VBD born_VBN in_IN
          the_DT United_NNP States_NNPS ,_, and_CC all_DT women_NNS reported_VBD country_NN of_IN
          birth_NN of_IN their_PRP$ parents_NNS to_TO be_VB in_IN Western_NNP Europe_NNP or_CC ,_, to_TO a_DT
          lesser_JJR degree_NN ,_, in_IN Eastern_NNP Europe_NNP ._.
          Women_NNP were_VBD considered_VBN postmenopausal_NN if_IN they_PRP were_VBD
          younger_JJR than_IN age_NN 50_CD years_NNS and_CC had_VBD natural_JJ menopause_NN ,_, had_VBD
          bilateral_JJ oophorectomy_NN or_CC had_VBD irradiation_NN to_TO the_DT ovaries_NNS ._.
          Women_NNP aged_VBN 50_CD years_NNS and_CC older_JJR were_VBD considered_VBN
          postmenopausal_NN if_IN they_PRP had_VBD ceased_VBN menstruation_NN ._. At_IN the_DT
          end_NN of_IN the_DT interview_NN ,_, women_NNS were_VBD asked_VBN to_TO provide_VB a_DT blood_NN
          specimen_NN ;_: 45_CD %_NN of_IN premenopausal_NN women_NNS and_CC 63_CD %_NN of_IN
          postmenopausal_NN women_NNS agreed_VBD ._. Among_IN pre-menopausal_JJ women_NNS ,_,
          there_EX were_VBD no_DT significant_JJ differences_NNS in_IN socioeconomic_JJ ,_,
          hormonal_NN ,_, reproductive_JJ ,_, or_CC dietary_JJ factors_NNS between_IN those_DT
          who_WP gave_VBD blood_NN and_CC those_DT who_WP refused_VBD ._. Among_IN
          postmenopausal_NN women_NNS ,_, controls_NNS who_WP gave_VBD a_DT blood_NN specimen_NN
          had_VBD a_DT greater_JJR mean_NN number_NN of_IN pregnancies_NNS (_( 3_CD ._. 5_LS versus_CC 2_CD ._. 9_CD ,_,
          
          P_NN <_NN 0_CD ._. 01_CD )_) than_IN those_DT who_WP
          declined_VBD ._. There_EX were_VBD no_DT other_JJ significant_JJ differences_NNS
          between_IN the_DT groups_NNS ._.
        
        
          Laboratory_NN analysis_NN
          DNA_NNP was_VBD purified_JJ by_IN standard_JJ phenol_NN /_NN chloroform_NN
          extraction_NN followed_VBN by_IN ethanol_NN precipitation_NN from_IN frozen_VBN
          blood_NN clots_NNS ._. PCR_NNP conditions_NNS were_VBD based_VBN on_IN those_DT of_IN Carey_NNP 
          et_CC al_NN ._. [_NN 19_CD ]_NN ._.
          Briefly_NNP ,_, genomic_JJ DNA_NNP (_( 50_CD ng_NN )_) was_VBD amplified_VBN using_VBG 50_CD
          pmol_NN primers_NNS (_( 5_CD '_POS -_: CAT_NNP TCG_NNP CAC_NNP TCT_NNP GGA_NNP GTC-_NNP 3_CD '_POS and_CC 5_CD '_POS -_: AGG_NNP
          CTC_NNP TTG_NNP GGG_NNP TAC_NNP TTG-_NNP 3_CD '_POS )_) in_IN GeneAmp_NNP PCR_NNP buffer_NN (_( 50_CD mM_NN KCl_NNP ,_,
          10_CD mM_NN Tris-_NNP HCl_NNP ,_, pH_NN 8_CD ._. 3_CD ,_, 0_CD ._. 001_CD %_NN [_NN w_NN /_NN v_NN ]_NN gelatin_NN ,_, 1_CD ._. 5_CD mM_NN MgCl_NNP
          
          2_LS ;_: Perkin_NNP Elmer_NNP ,_, Norwalk_NNP ,_, CT_NNP ,_, USA_NNP )_) ,_,
          and_CC Amplitaq_NNP DNA_NNP polymerase_NN (_( 2_CD ._. 5_LS U_NNP ;_: Perkin_NNP Elmer_NNP )_) with_IN
          2_CD '_POS -_: deoxynucleoside-_NN 3_CD '_POS -_: triphosphates_NNS (_( 1_CD ._. 87_CD mM_NN ;_: Pharmacia_NNP ,_,
          Piscataway_NNP ,_, NJ_NNP ,_, USA_NNP )_) in_IN a_DT 50_CD μl_NN reaction_NN volume_NN ._. The_DT PCR_NNP
          reaction_NN had_VBD an_DT initial_JJ melting_NN temperature_NN of_IN 94_CD °_NN C_NNP (_( 5_CD
          min_NN )_) followed_VBN by_IN 30_CD cycles_NNS of_IN melting_VBG (_( 94_CD °_NN C_NNP ,_, 1_CD min_NN )_) ,_,
          annealing_VBG (_( 56_CD °_NN C_NNP ,_, 1_CD min_NN )_) ,_, and_CC extension_NN (_( 72_CD °_NN C_NNP ,_, 1_CD min_NN )_) ._. An_DT
          extension_NN period_NN of_IN 7_CD min_NN at_IN 72_CD °_NN C_NNP followed_VBD the_DT final_JJ
          cycle_NN ._. The_DT resulting_VBG product_NN (_( 459_CD bp_NN )_) was_VBD subjected_VBN to_TO 
          Msp_NNP AI_NNP digest_VB (_( New_NNP England_NNP Biolabs_NNP ,_,
          Beverly_NNP ,_, MA_NNP ,_, USA_NNP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS
          directions_NNS ._. Gel_NNP electrophoresis_NNS (_( 2_CD ._. 2_LS %_NN agarose_NN ;_: Gibco_NNP BRL_NNP ,_,
          Gaithersburg_NNP ,_, MD_NNP ,_, USA_NNP )_) of_IN the_DT resulting_VBG fragments_NNS
          revealed_VBD either_CC the_DT A_DT 1_CD homozygote_NN (_( 459_CD bp_NN )_) ,_, the_DT A_DT 2_CD
          homozygote_NN (_( 335_CD and_CC 124_CD bp_NN )_) ,_, or_CC the_DT A_DT 1_CD /_NN A_DT 2_CD heterozygote_NN
          (_( 459_CD ,_, 335_CD ,_, and_CC 124_CD bp_NN )_) ._.
          Results_NNS of_IN genotyping_VBG for_IN the_DT study_NN were_VBD read_VBN from_IN the_DT
          gel_NN by_IN two_CD independent_JJ investigators_NNS ,_, and_CC at_IN least_JJS 20_CD %_NN of_IN
          the_DT samples_NNS were_VBD repeated_VBN for_IN quality_NN control_NN ._. The_DT assay_NN
          was_VBD validated_JJ by_IN confirming_VBG polymorphic_JJ Mendelian_NNP
          inheritance_NN patterns_NNS in_IN seven_CD human_JJ family_NN cell_NN lines_NNS (_( 
          n_NN =_SYM 134_CD )_) ,_, each_DT encompassing_VBG three_CD
          generations_NNS (_( data_NNS not_RB shown_VBN ;_: NIGMS_NNP Human_NNP Genetic_NNP Mutant_NNP
          Cell_NNP Repository_NNP ,_, Coriell_NNP Institute_NNP ,_, Camden_NNP ,_, NJ_NNP ,_, USA_NNP )_) ._.
        
        
          Statistical_NNP analysis_NN
          Tests_NNP for_IN Hardy-_NNP Weinberg_NNP equilibrium_NN among_IN controls_NNS
          were_VBD conducted_VBN using_VBG observed_VBN genotype_NN frequencies_NNS and_CC a_DT
          χ_NN 2_CD test_NN with_IN one_CD degree_NN of_IN freedom_NN ._. To_TO evaluate_VB the_DT role_NN
          of_IN 
          CYP_NNP 17_CD on_IN breast_NN cancer_NN risk_NN through_IN
          mediating_VBG mechanisms_NNS ,_, we_PRP first_RB assessed_VBN differences_NNS in_IN
          age_NN at_IN menarche_NN ,_, age_NN at_IN first_JJ full-term_JJ pregnancy_NN ,_,
          difficulty_NN in_IN becoming_VBG pregnant_JJ ,_, and_CC use_NN of_IN hormone_NN
          replacement_NN therapy_NN and_CC oral_JJ contraceptives_NNS among_IN
          controls_NNS according_VBG to_TO the_DT 
          CYP_NNP 17_CD genotype_NN ._.
          Data_NNS on_IN hormone_NN replacement_NN use_NN were_VBD only_RB available_JJ
          for_IN women_NNS who_WP were_VBD postmenopausal_NN ,_, and_CC few_JJ women_NNS beyond_IN
          menopause_NN had_VBD a_DT history_NN of_IN oral_JJ contraceptive_JJ use_NN ,_, so_RB
          only_RB premenopausal_NN women_NNS were_VBD included_VBN for_IN those_DT
          analyses_NNS ._. Odds_NNS ratios_NNS and_CC 95_CD %_NN confidence_NN intervals_NNS were_VBD
          calculated_VBN using_VBG unconditional_JJ logistic_JJ regression_NN to_TO
          evaluate_VB associations_NNS between_IN 
          CYP_NNP 17_CD genotypes_NNS and_CC breast_NN cancer_NN
          risk_NN separately_RB for_IN premenopausal_NN and_CC post-menopausal_JJ
          women_NNS ._. The_DT odds_NNS ratios_NNS were_VBD adjusted_VBN for_IN age_NN ,_, education_NN ,_,
          age_NN at_IN menarche_NN ,_, age_NN at_IN first_JJ pregnancy_NN ,_, reported_VBD family_NN
          history_NN of_IN breast_NN cancer_NN ,_, body_NN mass_NN index_NN ,_, history_NN of_IN
          benign_JJ breast_NN disease_NN ,_, and_CC age_NN at_IN menopause_NN for_IN
          postmenopausal_NN women_NNS ._.
          Associations_NNP between_IN hormonal_NN /_NN reproductive_JJ factors_NNS and_CC
          breast_NN cancer_NN were_VBD further_RBR calculated_VBN within_IN genotype_NN
          strata_NN ._. We_PRP performed_VBD tests_NNS for_IN interaction_NN by_IN computing_VBG
          the_DT crossproduct_NN of_IN the_DT independent_JJ variables_NNS (_( 
          CYP_NNP 17_CD and_CC reproductive_JJ factors_NNS
          whose_WP$ effects_NNS on_IN risk_NN varied_VBN by_IN genotype_NN )_) and_CC including_VBG
          it_PRP in_IN a_DT regression_NN model_NN with_IN its_PRP$ components_NNS entered_VBD
          separately_RB ._.
        
      
      
        Results_NNS
        Data_NNS in_IN the_DT present_JJ study_NN were_VBD available_JJ for_IN 182_CD
        pre-menopausal_JJ and_CC 214_CD postmenopausal_NN women_NNS ._. The_DT mean_JJ age_NN
        among_IN premenopausal_NN women_NNS was_VBD 47_CD years_NNS ,_, and_CC the_DT average_JJ age_NN
        of_IN postmenopausal_NN women_NNS was_VBD 63_CD years_NNS ._. We_PRP evaluated_VBD
        information_NN on_IN the_DT participant_NN 's_POS country_NN of_IN origin_NN and_CC
        their_PRP$ parent_NN 's_POS country_NN of_IN origin_NN ._. In_IN this_DT fairly_RB
        homogeneous_JJ population_NN ,_, all_DT of_IN the_DT women_NNS were_VBD of_IN European_JJ
        or_CC Eastern_JJ European_JJ decent_JJ ._. A_DT χ_NN 2_CD test_NN of_IN observed_VBD versus_CC
        expected_VBN genotype_NN frequencies_NNS for_IN 
        CYP_NNP 17_CD among_IN premenopausal_NN women_NNS
        suggested_VBD a_DT slight_JJ deviation_NN from_IN Hardy-_NNP Weinberg_NNP
        equilibrium_NN ._. However_RB ,_, this_DT difference_NN was_VBD not_RB statistically_RB
        significant_JJ (_( 
        P_NN =_SYM 0_CD ._. 08_CD )_) ._. The_DT genotype_NN frequencies_NNS
        for_IN post-menopausal_JJ women_NNS followed_VBD Hardy-_NNP Weinberg_NNP
        equilibrium_NN (_( 
        P_NN =_SYM 0_CD ._. 65_CD )_) ._.
        Hormonally_NNP related_VBD factors_NNS appeared_VBD to_TO vary_VB by_IN 
        CYP_NNP 17_CD genotype_NN (_( Table_NNP 1_LS )_) ._. Among_IN both_DT
        premenopausal_NN and_CC postmenopausal_NN women_NNS ,_, those_DT with_IN at_IN least_JJS
        one_CD A_DT 2_CD allele_NN were_VBD more_RBR likely_JJ than_IN women_NNS with_IN the_DT A_DT 1_CD /_NN A_DT 1_CD
        genotype_NN to_TO experience_VB early_JJ menarche_NN ,_, although_IN differences_NNS
        were_VBD not_RB statistically_RB significant_JJ ._. There_EX were_VBD also_RB slight_JJ
        differences_NNS in_IN age_NN at_IN menopause_NN ,_, with_IN a_DT somewhat_RB later_RB
        average_JJ age_NN at_IN menopause_NN for_IN women_NNS with_IN either_DT the_DT A_DT 1_CD /_NN A_DT 2_CD or_CC
        A_DT 2_CD /_NN A_DT 2_CD genotypes_NNS ._. Interestingly_RB ,_, postmenopausal_NN women_NNS with_IN
        at_IN least_JJS one_CD A_DT 2_CD allele_NN were_VBD also_RB less_RBR likely_JJ to_TO experience_VB
        difficulty_NN in_IN becoming_VBG pregnant_JJ and_CC ,_, correspondingly_RB ,_,
        tended_VBD to_TO have_VB children_NNS at_IN an_DT earlier_JJR age_NN ._. Contrary_JJ to_TO
        findings_NNS by_IN Feigelson_NNP 
        et_CC al_NN ._. [_NN 23_CD ]_NN ,_, the_DT 
        CYP_NNP 17_CD genotype_NN did_VBD not_RB influence_VB the_DT
        use_NN of_IN hormone_NN replacement_NN therapy_NN or_CC oral_JJ contraceptives_NNS
        in_IN the_DT present_JJ data_NN ._.
        Neither_DT homozygosity_NN nor_CC heterozygosity_NN for_IN the_DT A_DT 2_CD
        variant_NN was_VBD associated_VBN with_IN increased_VBN breast_NN cancer_NN risk_NN
        (_( Table_NNP 2_LS )_) ._. In_IN fact_NN ,_, there_EX appeared_VBD to_TO be_VB inverse_NN
        associations_NNS between_IN the_DT A_DT 2_CD allele_NN and_CC risk_NN ,_, particularly_RB
        among_IN postmenopausal_NN women_NNS ,_, in_IN both_DT unadjusted_JJ models_NNS and_CC
        those_DT models_NNS adjusted_VBN for_IN breast_NN cancer_NN risk_NN factors_NNS ._.
        Because_IN there_EX were_VBD few_JJ differences_NNS in_IN relationships_NNS for_IN
        those_DT with_IN A_DT 1_CD /_NN A_DT 2_CD and_CC A_DT 2_CD /_NN A_DT 2_CD genotypes_NNS ,_, these_DT categories_NNS were_VBD
        collapsed_VBN and_CC the_DT associations_NNS evaluated_VBN between_IN genotype_NN
        and_CC other_JJ breast_NN cancer_NN risk_NN factors_NNS ._.
        Associations_NNP between_IN breast_NN cancer_NN and_CC hormonal_NN risk_NN
        factors_NNS by_IN 
        CYP_NNP 17_CD genotype_NN are_VBP presented_VBN in_IN Table_NNP
        3_CD ._. For_IN premenopausal_NN women_NNS ,_, late_JJ age_NN at_IN menarche_NN was_VBD
        significantly_RB protective_JJ only_RB among_IN women_NNS with_IN A_DT 1_CD /_NN A_DT 1_CD
        alleles_NNS (_( odds_NNS ratio_NN =_SYM 0_CD ._. 37_CD ;_: 95_CD %_NN confidence_NN interval_NN =_SYM
        0_CD ._. 14_CD -_: 0_CD ._. 99_CD )_) ._. This_DT effect_NN was_VBD not_RB seen_VBN among_IN postmenopausal_NN
        women_NNS ._. Differences_NNS in_IN risk_NN were_VBD also_RB noted_VBN for_IN other_JJ
        factors_NNS ._. Late_RB age_NN at_IN first_JJ full-term_JJ pregnancy_NN
        significantly_RB increased_VBN risk_NN among_IN premenopausal_NN women_NNS only_RB
        for_IN those_DT with_IN the_DT A_DT 1_CD /_NN A_DT 1_CD genotype_NN ._. Risk_NN was_VBD also_RB elevated_VBD
        among_IN these_DT allele_NN carriers_NNS if_IN they_PRP reported_VBD use_NN of_IN oral_JJ
        contraceptives_NNS and_CC difficulty_NN becoming_VBG pregnant_JJ ._. For_IN
        postmenopausal_NN women_NNS ,_, it_PRP was_VBD women_NNS with_IN A_DT 2_CD alleles_NNS who_WP were_VBD
        most_JJS at_IN risk_NN of_IN breast_NN cancer_NN with_IN late_JJ age_NN at_IN first_JJ
        full-term_JJ pregnancy_NN and_CC with_IN difficulty_NN becoming_VBG pregnant_JJ ._.
        While_IN effects_NNS of_IN age_NN at_IN menarche_NN ,_, age_NN at_IN first_JJ full-term_JJ
        pregnancy_NN ,_, and_CC oral_JJ contraceptive_JJ use_NN were_VBD only_RB
        significantly_RB notable_JJ among_IN premenopausal_NN women_NNS with_IN A_DT 1_CD
        alleles_NNS ,_, interactions_NNS were_VBD not_RB statistically_RB significant_JJ
        (_( data_NNS not_RB shown_VBN )_) ._.
      
      
        Discussion_NNP
        We_PRP found_VBD in_IN the_DT present_JJ study_NN that_IN while_IN the_DT 
        CYP_NNP 17_CD Msp_NNP AI_NNP genetic_JJ polymorphism_NN did_VBD
        not_RB increase_VB breast_NN cancer_NN risk_NN ,_, it_PRP appears_VBZ to_TO modify_VB the_DT
        associations_NNS between_IN hormonal_NN and_CC reproductive_JJ factors_NNS and_CC
        breast_NN cancer_NN ._. Interestingly_RB ,_, women_NNS with_IN A_DT 2_CD alleles_NNS ,_, those_DT
        associated_VBN with_IN higher_JJR estrogen_NN levels_NNS in_IN both_DT
        premenopausal_NN and_CC postmenopausal_NN women_NNS ,_, were_VBD more_RBR likely_JJ to_TO
        share_VB characteristics_NNS associated_VBN with_IN greater_JJR fertility_NN ._.
        They_PRP were_VBD more_RBR likely_JJ to_TO have_VB an_DT earlier_JJR age_NN at_IN menarche_NN ,_,
        less_JJR difficulty_NN becoming_VBG pregnant_JJ ,_, an_DT earlier_JJR age_NN at_IN first_JJ
        full-term_JJ pregnancy_NN ,_, and_CC later_RB age_NN at_IN menopause_NN ._.
        In_IN accordance_NN with_IN previous_JJ studies_NNS [_NN 4_CD 9_CD 12_CD 16_CD ]_NN ,_,
        later_RB age_NN at_IN menarche_NN was_VBD protective_JJ against_IN breast_NN cancer_NN
        only_RB among_IN women_NNS homozygous_JJ for_IN the_DT A_DT 1_CD allele_NN ,_, although_IN we_PRP
        noted_VBD this_DT association_NN only_RB in_IN premenopausal_NN women_NNS ._.
        Furthermore_RB ,_, late_JJ age_NN at_IN first_JJ full-term_JJ pregnancy_NN and_CC oral_JJ
        contraceptive_JJ use_NN increased_VBD risk_NN only_RB among_IN premenopausal_NN
        women_NNS homozygous_JJ for_IN A_DT 1_CD alleles_NNS ._. Relationships_NNPS were_VBD not_RB as_IN
        notable_JJ among_IN postmenopausal_NN women_NNS ,_, although_IN late_JJ age_NN at_IN
        first_JJ birth_NN increased_VBD risk_NN only_RB among_IN women_NNS with_IN A_DT 2_CD
        alleles_NNS ._. These_DT apparent_JJ discrepancies_NNS by_IN menopausal_NN status_NN ,_,
        although_IN they_PRP may_MD be_VB due_JJ to_TO chance_NN ,_, could_MD reflect_VB
        differences_NNS in_IN the_DT nature_NN of_IN premenopausal_NN and_CC
        post-menopausal_JJ breast_NN cancer_NN etiology_NN ,_, particularly_RB in_IN
        relation_NN to_TO steroid_NN hormones_NNS ._.
        The_DT initial_JJ report_NN of_IN increased_VBN risk_NN of_IN breast_NN cancer_NN
        and_CC modification_NN of_IN other_JJ risk_NN factors_NNS by_IN variability_NN in_IN 
        CYP_NNP 17_CD was_VBD promising_JJ for_IN breast_NN cancer_NN
        research_NN [_NN 1_CD ]_NN ._. Steroid_NNP hormones_NNS clearly_RB play_VBP a_DT large_JJ role_NN
        in_IN breast_NN cancer_NN etiology_NN ,_, and_CC identification_NN of_IN risk_NN
        associated_VBN with_IN genetic_JJ differences_NNS in_IN their_PRP$ biosynthesis_NNS
        and_CC metabolism_NN could_MD greatly_RB elucidate_NN mechanistic_JJ pathways_NNS
        and_CC make_VB inroads_NNS towards_IN prevention_NN for_IN public_JJ health_NN ._.
        However_RB ,_, this_DT report_NN was_VBD followed_VBN by_IN a_DT number_NN of_IN studies_NNS
        that_WDT did_VBD not_RB corroborate_VBP those_DT early_JJ results_NNS ._. As_IN more_JJR
        studies_NNS have_VBP been_VBN conducted_VBN ,_, relationships_NNS between_IN the_DT 
        CYP_NNP 17_CD genotype_NN and_CC breast_NN cancer_NN risk_NN
        have_VBP become_VBN clearer_JJR ,_, particularly_RB through_IN the_DT repeated_VBN
        findings_NNS of_IN modification_NN of_IN risk_NN through_IN other_JJ reproductive_JJ
        factors_NNS ._. Because_IN two_CD studies_NNS have_VBP noted_VBN higher_JJR estrogen_NN
        levels_NNS among_IN women_NNS with_IN A_DT 2_CD alleles_NNS [_NN 4_CD 23_CD ]_NN ,_, it_PRP is_VBZ
        possible_JJ that_IN women_NNS with_IN these_DT genotypes_NNS have_VBP more_JJR lifetime_NN
        exposure_NN to_TO circulating_VBG steroid_NN hormones_NNS that_WDT is_VBZ not_RB
        abrogated_JJ by_IN later_RB age_NN at_IN menarche_NN or_CC by_IN earlier_JJR age_NN at_IN
        first_JJ full-term_JJ pregnancy_NN ._. Oral_NNP contraceptive_JJ use_NN may_MD
        similarly_RB only_RB impact_VB risk_NN in_IN an_DT environment_NN of_IN lower_JJR
        estrogens_NNS ._.
        Experimental_NNP studies_NNS [_NN 21_CD 22_CD ]_NN have_VBP shown_VBN that_IN the_DT 
        CYP_NNP 17_CD polymorphism_NN in_IN the_DT 5_CD '_POS -_: flanking_VBG
        region_NN of_IN the_DT gene_NN does_VBZ not_RB influence_VB binding_JJ to_TO Sp_NNP 1_CD ,_, as_RB
        previously_RB conjectured_JJ [_NN 1_CD 20_CD ]_NN ._. Nonetheless_RB ,_, studies_NNS in_IN
        both_DT premenopausal_NN women_NNS and_CC postmenopausal_NN women_NNS have_VBP
        found_VBN that_IN those_DT with_IN A_DT 2_CD alleles_NNS have_VBP higher_JJR circulating_VBG
        levels_NNS of_IN steroid_NN hormones_NNS ._. Thus_RB ,_, while_IN the_DT mechanism_NN
        whereby_WRB the_DT 
        CYP_NNP 17_CD polymorphism_NN increases_NNS serum_NN
        hormones_NNS levels_NNS has_VBZ not_RB been_VBN identified_VBN ,_, it_PRP is_VBZ probable_JJ
        that_IN there_EX are_VBP either_CC effects_NNS that_WDT have_VBP not_RB yet_RB been_VBN
        elucidated_JJ or_CC that_IN the_DT site_NN is_VBZ in_IN linkage_NN disequilibrium_NN
        with_IN another_DT polymorphism_NN that_IN alters_NNS the_DT function_NN of_IN the_DT 
        CYP_NNP 17_CD enzyme_NN ._.
        Results_NNS from_IN this_DT study_NN may_MD be_VB impacted_VBN by_IN a_DT number_NN of_IN
        factors_NNS ,_, foremost_RB of_IN which_WDT may_MD be_VB small_JJ sample_NN size_NN ._. While_IN
        we_PRP had_VBD data_NNS on_IN 395_CD women_NNS ,_, stratification_NN by_IN menopausal_NN
        status_NN and_CC additional_JJ stratification_NN by_IN 
        CYP_NNP 17_CD genotype_NN to_TO evaluate_VB
        differential_NN effects_NNS of_IN breast_NN cancer_NN risk_NN factors_NNS resulted_VBD
        in_IN small_JJ data_NNS points_NNS in_IN some_DT cells_NNS ,_, and_CC therefore_RB results_VBZ
        are_VBP interpreted_VBN cautiously_RB ._. Nonetheless_RB ,_, results_NNS support_VBP
        findings_NNS from_IN a_DT number_NN of_IN studies_NNS and_CC are_VBP consistent_JJ with_IN
        findings_NNS from_IN the_DT two_CD largest_JJS studies_NNS to_TO date_NN :_: those_DT from_IN
        the_DT Nurses_NNP '_POS Health_NNP Study_NNP [_NN 4_CD ]_NN and_CC the_DT study_NN of_IN breast_NN
        cancer_NN in_IN Finland_NNP [_NN 9_CD ]_NN ._. In_IN addition_NN ,_, our_PRP$ findings_NNS are_VBP in_IN
        accordance_NN with_IN those_DT of_IN a_DT meta-analysis_JJ of_IN 15_CD case-control_JJ
        studies_NNS [_NN 16_CD ]_NN ._.
        Furthermore_RB ,_, genotype_NN frequencies_NNS among_IN premenopausal_NN
        women_NNS deviated_VBD slightly_RB from_IN Hardy-_NNP Weinberg_NNP equilibrium_NN ,_,
        although_IN these_DT differences_NNS were_VBD not_RB statistically_RB
        significant_JJ ._. Previous_JJ studies_NNS have_VBP shown_VBN a_DT range_NN of_IN
        genotype_NN distributions_NNS ._. In_IN a_DT recent_JJ meta-analysis_JJ by_IN Ye_NNP and_CC
        Parry_NNP [_NN 16_CD ]_NN ,_, the_DT A_DT 2_CD /_NN A_DT 2_CD genotype_NN prevalence_NN ranged_VBD from_IN
        7_CD ._. 7_CD to_TO 23_CD ._. 4_LS %_NN among_IN Caucasian_NNP women_NNS in_IN 11_CD different_JJ studies_NNS ._.
        This_DT variability_NN in_IN estimates_NNS could_MD be_VB due_JJ ,_, in_IN part_NN ,_, to_TO
        small_JJ sample_NN sizes_NNS ._. In_IN the_DT present_JJ study_NN ,_, we_PRP found_VBD that_IN 11_CD %_NN
        of_IN premenopausal_NN controls_NNS and_CC 12_CD %_NN of_IN post-menopausal_JJ
        controls_NNS had_VBD the_DT A_DT 2_CD /_NN A_DT 2_CD genotype_NN ,_, which_WDT falls_VBZ well_RB within_IN
        this_DT range_NN ._. However_RB ,_, the_DT prevalence_NN of_IN heterozygotes_NNS was_VBD
        higher_JJR in_IN our_PRP$ population_NN than_IN in_IN other_JJ studies_NNS ._. It_PRP is_VBZ
        unlikely_JJ that_IN this_DT could_MD be_VB attributed_VBN to_TO population_NN
        stratification_NN ,_, since_IN western_JJ New_NNP York_NNP is_VBZ a_DT fairly_RB
        homogeneous_JJ area_NN ,_, and_CC women_NNS were_VBD all_DT of_IN European_JJ descent_NN
        and_CC ,_, for_IN the_DT most_JJS part_NN ,_, at_IN least_JJS second-generation_JJ or_CC
        third-generation_JJ Americans_NNPS ._. Another_DT possible_JJ explanation_NN
        for_IN the_DT higher_JJR proportion_NN of_IN heterozygotes_NNS could_MD be_VB
        genotyping_VBG errors_NNS ,_, although_IN two_CD independent_JJ investigators_NNS
        read_VBP the_DT gels_NNS and_CC at_IN least_JJS 20_CD %_NN of_IN the_DT samples_NNS were_VBD repeated_VBN
        for_IN quality_NN control_NN ._. Furthermore_RB ,_, assays_NNS were_VBD validated_JJ by_IN
        confirmation_NN of_IN polymorphic_JJ Mendelian_NNP inheritance_NN patterns_NNS
        in_IN seven_CD human_JJ family_NN cell_NN lines_NNS (_( 
        n_NN =_SYM 134_CD )_) ,_, each_DT encompassing_VBG three_CD
        generations_NNS ._.
        In_IN summary_NN ,_, our_PRP$ findings_NNS support_VBP those_DT of_IN several_JJ other_JJ
        studies_NNS that_WDT variant_NN 
        CYP_NNP 17_CD alleles_NNS modify_VB breast_NN cancer_NN
        risk_NN associated_VBN with_IN several_JJ hormonal_NN and_CC reproductive_JJ
        factors_NNS ._. These_DT collective_JJ findings_NNS may_MD point_VB the_DT way_NN toward_IN
        further_JJ investigations_NNS into_IN the_DT role_NN of_IN metabolic_JJ
        variability_NN in_IN steroidogenesis_NNS and_CC metabolism_NN in_IN relation_NN
        to_TO breast_NN cancer_NN risk_NN ,_, and_CC target_NN women_NNS who_WP may_MD be_VB most_JJS at_IN
        risk_NN for_IN the_DT disease_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        bp_NN =_SYM base_NN pairs_NNS ;_: PCR_NNP =_SYM polymerase_NN chain_NN reaction_NN ._.
      
    
  
